Every toxin on the market is grown from live bacteria, until now. Chinas regulator approved Retoxin, the worlds first recombinant botulinum toxin, made by genetic engineering rather than bacterial culture.
Chinas National Medical Products Administration (NMPA) approved Retoxin (by Claruvis Pharmaceutical), described as the worlds first recombinant botulinum toxin type A, for moderate-to-severe frown lines. Unlike conventional toxins grown from live bacteria, it is made via recombinant DNA technology. It is approved only in China, not FDA-approved or available in the U.S.
Botulinum toxin has been produced the same fundamental way for decades, by culturing the bacterium that makes it.
A 2026 approval in China points to a different manufacturing future.
Chongqing Claruvis Pharmaceutical announced that Chinas NMPA approved Retoxin, the worlds first recombinant botulinum toxin type A, for the temporary improvement of moderate-to-severe glabellar (frown) lines in adults. Reported broadly in early May, the milestone marks a shift from traditional production, extracting toxin from cultured Clostridium botulinum bacteria, to a precision-engineered recombinant process. The company says the approach preserves the active 150kDa neurotoxin structure while eliminating biosafety risks tied to live bacterial culture, delivering high purity and, per its data, low immunogenicity. A Phase 3 trial in China reportedly met all primary and secondary endpoints, and Claruvis is also pursuing a therapeutic use in post-stroke upper-limb spasticity.
The key caveat for U.S. readers: Retoxin is approved only in China. It is not FDA-approved and not available in the United States. Recombinant manufacturing is a notable technical advance, but approval in one market does not establish availability or regulatory clearance elsewhere.
For consumers, Retoxin signals where toxin manufacturing may evolve, potentially toward higher purity and consistency, but it is not something U.S. patients can access now. Claims of lower immunogenicity are promising in principle yet require independent, longer-term validation. The practical point is to distinguish a manufacturing milestone abroad from a treatment option at home; the two are not the same.
Watch whether recombinant toxins pursue regulatory pathways in other markets, including the U.S., and whether real-world data confirms the purity and immunogenicity advantages claimed. If the approach proves out, it could influence the broader toxin category over time. For now, U.S. patients should treat Retoxin as international news, and rely on FDA-approved toxins administered by qualified providers.